Ultragenyx Pharmaceutical (RARE) Scheduled to Post Quarterly Earnings on Wednesday

Ultragenyx Pharmaceutical (NASDAQ:RARE) is scheduled to be issuing its quarterly earnings data after the market closes on Wednesday, February 14th. Analysts expect the company to announce earnings of ($1.96) per share for the quarter.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) EPS for the quarter, hitting the Zacks’ consensus estimate of ($1.87). The company had revenue of $0.20 million during the quarter, compared to the consensus estimate of $0.02 million. Ultragenyx Pharmaceutical’s revenue was up 81.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.64) earnings per share. On average, analysts expect Ultragenyx Pharmaceutical to post $-7 EPS for the current fiscal year and $-7 EPS for the next fiscal year.

Ultragenyx Pharmaceutical (NASDAQ RARE) opened at $47.91 on Wednesday. The company has a market cap of $2,040.00, a PE ratio of -6.87 and a beta of 1.89. Ultragenyx Pharmaceutical has a one year low of $43.14 and a one year high of $91.35.

RARE has been the topic of a number of research analyst reports. Canaccord Genuity set a $80.00 target price on shares of Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a research note on Tuesday, December 5th. Barclays upped their price target on shares of Ultragenyx Pharmaceutical from $60.00 to $62.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 5th. Evercore ISI raised shares of Ultragenyx Pharmaceutical from an “in-line” rating to an “outperform” rating in a research report on Monday, January 22nd. Zacks Investment Research raised shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Wednesday, November 8th. Finally, BidaskClub cut shares of Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday, December 12th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $72.06.

ILLEGAL ACTIVITY WARNING: “Ultragenyx Pharmaceutical (RARE) Scheduled to Post Quarterly Earnings on Wednesday” was published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/07/ultragenyx-pharmaceutical-rare-scheduled-to-post-quarterly-earnings-on-wednesday.html.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Earnings History for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply